- Home
- ABEO vs MNPR Comparison
ABEO vs MNPR Comparison
Compare ABEO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- MNPR
- Stock Information
- Founded
- ABEO 1974
- MNPR 2014
- Country
- ABEO United States
- MNPR United States
- Employees
- ABEO N/A
- MNPR N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ABEO Health Care
- MNPR Health Care
- Exchange
- ABEO Nasdaq
- MNPR Nasdaq
- Market Cap
- ABEO 256.9M
- MNPR 249.5M
- IPO Year
- ABEO 1980
- MNPR 2019
- Fundamental
- Price
- ABEO $5.93
- MNPR $32.86
- Analyst Decision
- ABEO Strong Buy
- MNPR Strong Buy
- Analyst Count
- ABEO 6
- MNPR 5
- Target Price
- ABEO $18.00
- MNPR $59.50
- AVG Volume (30 Days)
- ABEO 870.0K
- MNPR 24.2K
- Earning Date
- ABEO 08-11-2025
- MNPR 08-08-2025
- Dividend Yield
- ABEO N/A
- MNPR N/A
- EPS Growth
- ABEO N/A
- MNPR N/A
- EPS
- ABEO N/A
- MNPR N/A
- Revenue
- ABEO N/A
- MNPR N/A
- Revenue This Year
- ABEO N/A
- MNPR N/A
- Revenue Next Year
- ABEO $323.51
- MNPR N/A
- P/E Ratio
- ABEO N/A
- MNPR N/A
- Revenue Growth
- ABEO N/A
- MNPR N/A
- 52 Week Low
- ABEO $3.93
- MNPR $1.72
- 52 Week High
- ABEO $7.32
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- ABEO 45.53
- MNPR 42.95
- Support Level
- ABEO $6.10
- MNPR $33.00
- Resistance Level
- ABEO $6.24
- MNPR $35.01
- Average True Range (ATR)
- ABEO 0.29
- MNPR 2.68
- MACD
- ABEO -0.09
- MNPR 0.00
- Stochastic Oscillator
- ABEO 4.26
- MNPR 32.27
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.